With its lead CAR-T flash­ing some PhI da­ta, Ar­cel­lx read­ies a jump to Nas­daq

4 years ago
Financing

Q&A: Bio­Marin com­mer­cial chief Jeff Ajer gears up for biggest drug launch to date — with an­oth­er wait­ing in the ...

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Aduhelm can’t get trac­tion with docs; Pfiz­er press­es vac­cine ef­fort dur­ing NFL play­offs

4 years ago
Pharma
Marketing

Ogilvy Health’s new chief cre­ative of­fi­cer Adam Hes­sel con­tem­plates cre­ative pros and cons of Covid

4 years ago
Pharma
Marketing

En­do reach­es opi­oid set­tle­ment in Flori­da; De­moc­rats call on CMS to low­er pre­mi­ums fol­low­ing Aduhelm price cut

4 years ago
News Briefing

UK up­start rais­es $100M in bid to dig­i­tize and stan­dard­ize cell and gene ther­a­py man­u­fac­tur­ing

4 years ago
Cell/Gene Tx
Manufacturing

Se­ma4 shells out $623M to scoop up a lead­ing di­ag­nos­tics play­er and its trove of da­ta

4 years ago
Deals

Hal Bar­ron keeps 23andMe close on GSK's side to find more genes the R&D team can go af­ter

4 years ago
Deals

Bil­lion­aires Chamath Pal­i­hapi­tiya and Pablo Legor­re­ta hatch an $825M SPAC for cell ther­a­py biotech

4 years ago
Financing

No stranger to head­winds, blue­bird runs in­to two PDU­FA de­lays un­re­lat­ed to new safe­ty is­sues

4 years ago
R&D
FDA+

With few re­main­ing un­ap­proved drugs, re­searchers tell FDA its Un­ap­proved Drugs Ini­tia­tive is no longer ef­fec­tive

4 years ago
FDA+

CBO: Medicare ne­go­ti­a­tions will ham­per drug de­vel­op­ment more than pre­vi­ous­ly thought

4 years ago
Pharma
FDA+

FDA or­ders DMD tri­al halt, rais­ing ques­tions about a whole class of promis­ing drugs

4 years ago
R&D
Cell/Gene Tx

An­ti­body leg­end Till­man Gern­gross in­tro­duces his lat­est com­pa­ny, with an In­novent deal al­ready lined up

4 years ago
Startups
Deals

Covid-19 roundup: Pfiz­er ex­pands in­to France; Omi­cron-spe­cif­ic ver­sion of Mod­er­na's boost­er com­ing soon 

4 years ago
Coronavirus

Tiny biotech ham­mered as lead drug fails a key PhII study

4 years ago
R&D

Ready for an M&A fight? Af­ter GSK shunned $68B of­fer, Unilever says it's still in hunt for con­sumer health JV

4 years ago
Deals
Pharma

Mar­tin Shkre­li re­ceives life­time in­dus­try ban, forced to re­turn al­most $65M in prof­its af­ter an­ti­com­pet­i­tive scheme

4 years ago
People
Pharma

Ar­genx de­buts first DTC for myas­the­nia gravis med Vyv­gart even as MG com­mu­ni­ty ef­fort con­tin­ues

4 years ago
Pharma
Marketing

Covid vac­cine mak­ers Pfiz­er, J&J notch high brand marks amid over­all still-strong phar­ma in­dus­try rep: Har­ris Poll

4 years ago
Pharma
Marketing

Ten months af­ter dev­as­tat­ing fail­ure, Roche says it sees path for­ward for Hunt­ing­ton’s drug

4 years ago
R&D

Lat­est news on Pfiz­er's $3B+ JAK1 win; Pacts over M&A at #JPM22; 2021 by the num­bers; Bio­gen's Aduhelm reck­on­ing; The ...

4 years ago
Weekly

A $3B+ peak sales win? Pfiz­er thinks so, as FDA of­fers a tardy green light to its JAK1 drug abroc­i­tinib

4 years ago
Pharma
FDA+

Vir ex­pands part­ner­ship with Gates Foun­da­tion, adding $50M for HIV and malar­ia an­ti­body re­search ini­tia­tive

4 years ago
Deals
First page Previous page 589590591592593594595 Next page Last page
A service from the Financial Times